{"count": 2, "results": [{"_id": "33210751", "pmid": 33210751, "title": "Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.", "journal": "Cochrane Database Syst Rev", "authors": ["Ipsen EØ", "Madsen KS", "Chi Y", "Pedersen-Bjergaard U", "Richter B", "Metzendorf MI", "Hemmingsen B"], "date": "2020-11-19T00:00:00Z", "doi": "10.1002/14651858.CD013516.pub2", "meta_date_publication": "2020 Nov 19", "meta_volume": "11", "meta_issue": "11", "meta_pages": "CD013516", "score": 50222.05, "text_hl": "The data and reporting of all-cause mortality, SAEs, @<m>DISEASE_Warburg_Sjo_Fledelius_syndrome</m> @DISEASE_MESH:C536681 @@@micro- and macrovascular complications@@@ were generally sparse. ", "citations": {"NLM": "Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. PMID: 33210751", "BibTeX": "@article{33210751, title={Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.}, author={Ipsen EØ and Madsen KS and Chi Y and Pedersen-Bjergaard U and Richter B and Metzendorf MI and Hemmingsen B}, journal={Cochrane Database Syst Rev}, volume={11}, number={11}, pages={CD013516}}"}}, {"_id": "22775758", "pmid": 22775758, "title": "Overview of metformin: special focus on metformin extended release.", "journal": "Expert Opin Pharmacother", "authors": ["Ali S", "Fonseca V"], "date": "2012-08-01T00:00:00Z", "doi": "10.1517/14656566.2012.705829", "meta_date_publication": "2012 Aug", "meta_volume": "13", "meta_issue": "12", "meta_pages": "1797-805", "score": 50070.285, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ XR can be given once daily and is associated with less GI side effects compared to immediate release @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (IR); This leads to increased compliance, improved glycemic control and hence decreased risk of the associated @<m>DISEASE_Warburg_Sjo_Fledelius_syndrome</m> @DISEASE_MESH:C536681 @@@micro- and macro-vascular complications@@@.", "citations": {"NLM": "Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother. 2012 Aug;13(12):1797-805. PMID: 22775758", "BibTeX": "@article{22775758, title={Overview of metformin: special focus on metformin extended release.}, author={Ali S and Fonseca V}, journal={Expert Opin Pharmacother}, volume={13}, number={12}, pages={1797-805}}"}}]}